Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Innovative Research Inc Hmn Tp I Colgn Sol 3mg/mL 20ml

Supplier:  Innovative Research Inc IHUCLGMA20ML

Encompass_Preferred

Human Type I Collagen Solution 3mg/mL 20ml - This Protein is recombinantly produced in HEK293 cells. This is a Lyophilized protein buffered in PBS, pH7.4 with a purity of >90% as determined by SDS-PAGE. CD94(Natural killer cells antigen CD94) is also known as KLRD1, KP43, NK cell receptor, Killer cell lectin-like receptor subfamily D member 1. CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminal. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells. This protein carries a polyhistidine Tag at the C-terminal. The protein has a calculated MW of 19.1 kDa. The protein migrates as 24-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Catalog No. 50-274-4346


May include imposed supplier surcharges.
Only null left
Add to Cart

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.